Leif G Lindholm

Title: Leif G Lindholm: Innovator in Monoclonal Antibody Development

Introduction

Leif G Lindholm is a notable inventor based in Kullavik, Sweden. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has implications for both therapeutic and diagnostic applications in medicine.

Latest Patents

Lindholm holds a patent for a tumor antigen-specific antibody. This monoclonal antibody reacts with the CA-242 antigen and can be obtained by culturing the hybridoma cell line C242:II, which has the ECACC identification number 90012601. The patent also includes provisions for cell lines that produce this antibody, highlighting its potential utility in medical treatments and diagnostics.

Career Highlights

Lindholm has been associated with Pharmacia Aktiebolag, a company known for its advancements in pharmaceuticals and biotechnology. His work at Pharmacia has allowed him to focus on innovative solutions in the medical field, particularly in cancer treatment.

Collaborations

Throughout his career, Lindholm has collaborated with esteemed colleagues such as Jan Holmgren and Peter Lind. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Leif G Lindholm's contributions to the field of monoclonal antibodies exemplify the impact of innovation in biotechnology. His patent for a tumor antigen-specific antibody represents a significant advancement in medical science, showcasing the importance of research and collaboration in developing effective therapeutic solutions.